Trial Profile

A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dalcetrapib (Primary)
Indications Acute coronary syndromes; Cardiovascular disorders; Coronary disorders; Myocardial infarction; Stroke
Focus Registrational; Therapeutic Use
Acronyms dal-OUTCOMES
Sponsors Roche

Most Recent Events

06 Mar 2020 Results published in the Diabetes Care
16 Dec 2019 Results (n=1378) of a nested case cohort subgroup analysis assessing association of high density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome were published in the American Heart Journal
09 Aug 2017 This study has been discontinued in Belgium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com